<DOC>
	<DOCNO>NCT02141997</DOCNO>
	<brief_summary>This study Phase 2 randomize , double-blind , double-dummy , parallel-group study design assess safety , tolerability , efficacy , pharmacokinetics immunogenicity multiple dos ABT 122 subject active rheumatoid arthritis ( RA ) inadequately respond methotrexate ( MTX ) treatment .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy ABT-122 Given With Methotrexate Subjects With Active Rheumatoid Arthritis Who Have Inadequate Response Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Adult male female , 18 year age old . 2 . Diagnosis RA base 2010 American College Rheumatology ( ACR ) /European League Rheumatism ( EULAR ) criterion ( define definition term ) . 3 . Rheumatoid Arthritis ( RA ) diagnosis least 3 month date first Screening . 4 . Have active RA define minimum disease activity criterion : ≥ 6 Swollen joint ( base 66 joint count ) screen baseline visit . ≥ 6 Tender joint ( base 68 joint count ) screen baseline visit . hsCRP &gt; ULN OR positive Rheumatoid Factor ( RF ) AntiCyclic Citrullinated Peptide ( AntiCCP ) Antibody level screen . 5 . Inadequate response Methotrexate ( MTX ) treatment define oral parenteral treatment ≥ 3 month unchanged mode application stable prescribed MTX dose least 4 week prior baseline ≥ 10mg/week &lt; upper limit applicable approve local label . Subject also stable dos sulfasalazine and/or hydroxychloroquine , long also methotrexate . 1 . Subject previous exposure Humira , Tumor necrosis factor ( TNF ) inhibitor biological DMARDs . 2 . Current treatment traditional oral Disease modify antirheumatic drug ( DMARDs ) ( except concomitant treatment sulfasalazine and/or hydroxychloroquine addition MTX ) . Oral DMARDs must wash 5 time mean terminal elimination halflife drug apart MTX prior Day 1 . • Subject could expose prior Janus kinase ( JAK ) inhibitor long therapy 5 halflives . 3 . Stable prescribed dose oral prednisone prednisone equivalent &gt; 10 mg/day within 30 day first dose study drug . 4 . Intraarticular parenteral administration corticosteroid precede 4 week first dose study drug . Inhaled corticosteroid stable medical condition allow . 5 . Laboratory value follow Screening Visit : Confirmed hemoglobin &lt; 9 g/dL male &lt; 8.5 g/dL female , Absolute neutrophil count ( ANC ) &lt; 1500 mm^3 , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 1.5 × upper limit normal ( ULN ) bilirubin ≥ 3 mg/dL , Serum creatinine &gt; 1.5 × ULN , Platelets &lt; 100,000 cells/ [ mm3 ] ( 10^9/L ) , Clinically significant abnormal screen laboratory result evaluate Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>efficacy</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>safety</keyword>
</DOC>